L-W Huang1, S-L Chao, B-H Lee. 1. Department of Obstetrics and Gynecology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan. m002057@ms.skh.org.tw
Abstract
AIM: Human papillomavirus (HPV) integration is a critical event in cervical carcinogenesis. The aim of this study was to explore the physical status of HPV-16 and HPV-18 during the progression of cervical precancerous lesions. METHODS: A series of 101 HPV-16 or HPV-18 positive cervical neoplasms (32 cervical intraepithelial neoplasia (CIN) cases and 69 cervical carcinoma (CC) cases) were evaluated. The physical status of both types of HPV was assessed from paraffin-embedded formaldehyde-fixed surgical specimens by real-time PCR. RESULTS: For HPV-16, integrated DNA was observed in 5 (83.3%) of 6 CIN I cases, 10 (90.9%) of 11 CIN II/III cases, 29 (82.9%) of 35 FIGO (International Federation of Gynecology and Obstetrics) stage I CC cases and 16 (94.1%) of 17 FIGO stages II approximately IV CC cases. For HPV-18, integrated DNA was observed in 3 (50%) of 6 CIN I cases, 5 (55.6%) of 9 CIN II/III cases, 9 (64.3%) of 14 FIGO stage I CC cases, and 1 (33.3%) of 3 FIGO stages II approximately IV CC cases. The mixed form of HPV DNA was the most prevalent physical state in HPV-16. There was no significant difference between the physical state of HPV-16 and HPV-18 DNA with regard to the various grades of cervical lesions. CONCLUSIONS: These data imply that integration of HPV-16 and HPV-18 DNA into the host genome occurs in the very early stage of cervical neoplastic progression. These early events may play an initiating role in the malignant transformation of HPV-16- and HPV-18-related low-grade lesions into high-grade dysplasia and invasive carcinoma.
AIM: Human papillomavirus (HPV) integration is a critical event in cervical carcinogenesis. The aim of this study was to explore the physical status of HPV-16 and HPV-18 during the progression of cervical precancerous lesions. METHODS: A series of 101 HPV-16 or HPV-18 positive cervical neoplasms (32 cervical intraepithelial neoplasia (CIN) cases and 69 cervical carcinoma (CC) cases) were evaluated. The physical status of both types of HPV was assessed from paraffin-embedded formaldehyde-fixed surgical specimens by real-time PCR. RESULTS: For HPV-16, integrated DNA was observed in 5 (83.3%) of 6 CIN I cases, 10 (90.9%) of 11 CIN II/III cases, 29 (82.9%) of 35 FIGO (International Federation of Gynecology and Obstetrics) stage I CC cases and 16 (94.1%) of 17 FIGO stages II approximately IV CC cases. For HPV-18, integrated DNA was observed in 3 (50%) of 6 CIN I cases, 5 (55.6%) of 9 CIN II/III cases, 9 (64.3%) of 14 FIGO stage I CC cases, and 1 (33.3%) of 3 FIGO stages II approximately IV CC cases. The mixed form of HPV DNA was the most prevalent physical state in HPV-16. There was no significant difference between the physical state of HPV-16 and HPV-18 DNA with regard to the various grades of cervical lesions. CONCLUSIONS: These data imply that integration of HPV-16 and HPV-18 DNA into the host genome occurs in the very early stage of cervical neoplastic progression. These early events may play an initiating role in the malignant transformation of HPV-16- and HPV-18-related low-grade lesions into high-grade dysplasia and invasive carcinoma.
Authors: J R Montealegre; E C Peckham-Gregory; D Marquez-Do; L Dillon; M Guillaud; K Adler-Storthz; M Follen; M E Scheurer Journal: Gynecol Oncol Date: 2017-12-21 Impact factor: 5.482
Authors: Jo L K Cheung; Tak-Hong Cheung; Candy W Y Ng; Mei Y Yu; Martin C S Wong; Shing-Shun N Siu; So-Fan Yim; Paul K S Chan Journal: J Clin Microbiol Date: 2008-11-26 Impact factor: 5.948
Authors: Francisco Israel Torres-Rojas; Luz Del Carmen Alarcón-Romero; Marco Antonio Leyva-Vázquez; Julio Ortiz-Ortiz; Miguel Ángel Mendoza-Catalán; Daniel Hernández-Sotelo; Oscar Del Moral-Hernández; Hugo Alberto Rodríguez-Ruiz; Dinorah Leyva-Illades; Eugenia Flores-Alfaro; Berenice Illades-Aguiar Journal: Oncol Lett Date: 2017-12-13 Impact factor: 2.967
Authors: Caroline L P Muntinga; Peggy J de Vos van Steenwijk; Ruud L M Bekkers; Edith M G van Esch Journal: J Clin Med Date: 2022-03-05 Impact factor: 4.241